Introduction
Adenosine is an essential neuromodulator in the brain, and has been shown to play a role in both physiological (Hogan et al., 1998) and pathophysiological (Chen et al., 2001; Rudolphi and Schubert, 1995) processes, although the mechanism by which adenosine Abbreviations: CPA, N 6 -cyclopentyl adenosine; DPCPX, 8-cyclopentyl-1,3-dipropylxanthine; APSD, adenosine-induced persistent synaptic depression; A1R, adenosine A1 receptor; A2AR, adenosine A2A receptor; fEPSP, field excitatory postsynaptic potential; aCSF, artificial cerebrospinal fluid; AMPAR, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; CP-AMPAR, calcium permeable AMPAR; NMDAR, N-methyl-D-aspartate receptor; PI, propidium iodide; p38 MAPK, p38 mitogenactivated protein kinase; JNK, c-Jun N-terminal kinase; PP2A, protein phosphatase 2A; PP1, protein phosphatase 1; PP2B, protein phosphatase 2B.
receptors modulate synaptic activity is less well understood. Of the four known G-protein-coupled adenosine receptors (A1, A2A, A2B, and A3), A1 and A2A receptors (A1R, A2AR) have well classified neuromodulatory functions in the central nervous system, with opposing inhibitory and excitatory actions, respectively (Sichardt and Nieber, 2007) . During situations of neuronal stress, extracellular adenosine concentrations increase drastically from extracellular ATP breakdown and adenosine extrusion from stressed cells (Dale et al., 2000; Pearson et al., 2001) . High levels of adenosine in the hippocampus cause increased A1R activation and subsequent synaptic depression (Chen et al., 2014) . A1R-induced synaptic depression is thought to afford neuroprotection to ischemic cells by preventing excitotoxicity during metabolic stress presynaptically by inhibiting glutamate release (Liu et al., 2006; Obrietan et al., 1995) and postsynaptically by reducing neuronal excitability (Cunha, 2005) .
We recently showed that A1R activation causes rapid clathrinmediated endocytosis of excitatory a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) through both a physical and functional interaction (Chen et al., 2014) . Specifically, A1Rs interact with GluA1 and GluA2 AMPAR subunits to induce their endocytosis. We showed that p38 mitogen-activated protein kinase (MAPK), c-Jun N-terminal kinase (JNK) and protein phosphatase 2A (PP2A) inhibition prevented adenosine-induced GluA1-and GluA2-containing AMPAR internalization, although inhibition of p38 and JNK did not entirely prevent A1R-induced GluA1 internalization (Chen et al., 2014) . Additionally, prolonged A1R activation induced adenosine-induced persistent synaptic depression (APSD) in CA1 of rat hippocampal slices. However, the precise cellular mechanism of APSDs in the hippocampus remains to be established. GluA1 plays an essential role in fast excitatory synaptic transmission in the hippocampus, such as the induction of certain forms of synaptic plasticity (Lee et al., 2010) , and is present in a majority of hippocampal neurons (Rogers et al., 1991) . Of particular importance, GluA1 homomers are permeable to Ca 2þ , and their overexpression has been shown to play a role in ischemiainduced neuronal death (Kwak and Weiss, 2006) . Accordingly, blockade of Ca 2þ -permeable AMPARs (CP-AMPARs) has been shown to reduce ischemia-induced neuronal death in the brain (Noh et al., 2005) . It follows that A1R-induced GluA1 internalization may contribute in the short term (within minutes) to prevent acute excitotoxicity during neurotoxic stimuli such as in cerebral ischemia. However, whether changes in the levels of GluA1 and GluA2 AMPAR surface expression are linked to persistent A1R signaling that contributes to hippocampal neuronal damage has never been previously studied. GluA1 surface expression is known to be regulated in part by the phosphorylation state of two major C-terminal serine residues of GluA1, namely Ser831 and Ser845, which control multiple functions of GluA1 such as surface expression, synaptic translocation, channel open probability, and channel conductance (Lee et al., 2003) . Phosphorylation of Ser831 and Ser845 by PKC/CaMKII and PKA, respectively, has been shown to induce increased GluA1 surface expression and synaptic localization (Esteban et al., 2003; Gu et al., 1996; He et al., 2011) . Alternately, dephosphorylation of Ser831 and Ser845 has also been shown to mediate a reduction in the surface expression of GluA1 (Beattie et al., 2000; Lee et al., 2010; Oh et al., 2006) . We previously showed that A1R activation induced downregulation of phospho-Ser845 (pSer845) that accompanies A1R-induced GluA1 endocytosis (Chen et al., 2014) . In the present study, we further examined the role of serine/ threonine phosphatases in modulating the phosphorylation of Ser831 and Ser845 of GluA1 subunits. Three major serine/threonine phosphatases present in hippocampal neurons are protein phosphatase 1 (PP1), PP2A, and PP2B/calcineurin (Don Yi and Simpkins, 2008) , all of which have increased activity in hypoxia and ischemia (Brust et al., 2006; H edou et al., 2008; ShintaniIshida and Yoshida, 2011) . PP1, PP2A, and PP2B have been shown to play a role in different neuroprotective mechanisms and cellular responses to neuronal insult conditions, as well as AMPAR and N-methyl-D-aspartate receptor (NMDAR) modulation in the hippocampus (Beattie et al., 2000; Belmeguenai and Hansel, 2005; Don Yi and Simpkins, 2008; H edou et al., 2008) . A1R stimulation induces multiple intracellular signals, including the recruitment of PP2A to the cellular membrane of hippocampal neurons (Brust et al., 2006) . Therefore, we hypothesized that PP1, PP2A and PP2B function mediates A1R-induced GluA1 dephosphorylation, which contributes to A1R-induced GluA1 internalization and persistent synaptic inhibition.
We tested this hypothesis using electrophysiological, biochemical and confocal imaging analyses of rat hippocampal slices with exposure to selective protein phosphatase inhibitor drugs in the presence of N 6 -cyclopentyladenosine (CPA), a selective A1R agonist, and hypoxia/reperfusion conditions. We found that inhibition of PP1, PP2A, and PP2B reduced APSDs and GluA1 endocytosis in rat hippocampal slices after CPA treatment, but PP2A inhibition selectively prevented GluA2 internalization. Treatment with protein phosphatase inhibitors or A1R antagonist also reduced both CPA-mediated and hypoxia/reperfusion-induced hippocampal neuronal death. These results indicate a previously unrecognized mechanism of neuronal death in the vulnerable tissue of the hippocampus, whereby the A1R signaling through protein phosphatase activation triggers the formation of GluA2-deficient AMPARs on hippocampal membranes, which leads to increased hypoxiainduced neuronal death.
Materials and methods

Animals and ethics statement
All animal care and experimental procedures were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH publications No. 85-23, revised 1985) , and also conformed to guidelines of the Canadian Council for Animal Care (CCAC) under the supervision of the University of Saskatchewan Committee on Animal Care and Supply (Approved Animal Use Protocol Number: 20070090). The following experimental design, analysis and reported number of research animals used also complied with the ARRIVE guidelines for reporting experiments involving animal use to ensure all efforts were made to minimize animal suffering and the number of animals used in this study (Kilkenny et al., 2010) . Male SpragueeDawley rats (post-natal 18e30 days) were housed in cages in groups of three or four, maintained at 20e24 C with a natural lightedark cycle. Rats were purchased from Charles River Canada (Montreal, Quebec, Canada). All animals had unlimited access to standard pelleted diet and tap water.
Hippocampal slice preparation
Young male SpragueeDawley rats (post-natal18-30 days) were anaesthetized with halothane and rapidly decapitated, with the brains immediately excised and submerged in oxygenated, ice-cold high-sucrose dissection medium containing the following (in mM): 87 NaCl, 25 NaHCO 3 , 25 glucose, 75 sucrose, 2.5 KCl, 1.25 NaH 2 PO 4 , 7.0 MgCl 2 , and 0.5 CaCl 2 (Brust et al., 2007; Chen et al., 2014) .
Hippocampal slices were taken at 400 mm thickness using a vibrating tissue slicer (VTS1200S, Vibram Instruments, Germany), and slicing was performed in the same ice-cold oxygenated dissection medium as above. Slices were maintained for at least 1 h at room temperature in oxygenated artificial cerebrospinal fluid (aCSF) containing the following (in mM): 126 NaCl, 2.5 KCl, 2.0 MgCl 2 , 1.25 NaH 2 PO 4 , 26 NaHCO 3 , 10 glucose, 2.0 CaCl 2 (Brust et al., 2007; Chen et al., 2014) . Oxygenation was accomplished by continually aerating the solution with 95% O 2 /5% CO 2 .
Drug treatments
Hippocampal slices were incubated in one of the following treatments: dimethyl sulfoxide (DMSO, vehicle control, Sigma, St. Louis, MO), fostriecin (20 nM, Tocris, Bristol, UK), okadaic acid (3 nM, 20 nM, Tocris), tautomycetin (20 nM, Tocris), and FK506 (50 nM, Sigma). Fostriecin and okadaic acid are PP2A inhibitors, tautomycetin is a PP1 inhibitor, and FK506 is a PP2B inhibitor. The pharmacological inhibitor concentrations used are at least 10 times the reported IC50 values or similar to those previously demonstrated to be effective in hippocampal slices (H edou et al., 2008; Launey et al., 2004; Sharkey and Butcher, 1994; Uchino et al., 2002; Walsh et al., 1997) . N 6 -cyclopentyladenosine (CPA) was used as a selective adenosine A1R agonist at 500 nM, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) (Sigma) was used as a selective adenosine A1R antagonist at 500 nM. All drugs were dissolved in DMSO (Sigma) before being added to aCSF. The final concentration of DMSO was <0.1% in each treatment and bath incubation.
Electrophysiology
Hippocampal slices were submerged in an electrophysiology recording chamber with constant perfusion of oxygenated aCSF (3 ml/min) containing the appropriate drug treatment. As previously described (Brust et al., 2007 (Brust et al., , 2006 Chen et al., 2014) , field excitatory postsynaptic potentials (fEPSPs) were evoked by orthodromic stimulation of the Schaffer collateral pathway using a bipolar tungsten stimulating electrode, and fEPSP signals were digitized at 10 kHz using Digidata 1440A interface board and analyzed using Clampfit 9.0 (Axon Instruments, Foster City, CA). A recording microelectrode filled with aCSF was placed in CA1 stratum radiatum. The fEPSPs were evoked using 0.1 ms pulses every 30 s throughout each experiment. A stable baseline recording of at least 20 min was used, followed by a 30 min CPA treatment or a 20 min hypoxic insult and a subsequent 1 h washout period. Hypoxia was achieved by bubbling aCSF with 95% N 2 /5%CO 2 for at least 20 min, as previously described (Brust et al., 2006 (Brust et al., , 2007 Chen et al., 2014) . Although O 2 was replaced with N 2 , the bubbling solution was in an open container and the recording chamber was open to air, so the recording solution was considered hypoxic. The fEPSP slopes were normalized to the mean of the 10 sweeps (5 min) immediately preceding drug perfusion. Statistical significance was assessed using one-way analysis of variance (ANOVA) with TukeyeKramer post-hoc test.
Biochemistry
Biochemical methods used are outlined in a recent report (Chen et al., 2014) . In short, following appropriate drug incubation, brain slices were treated with CPA for 30 min or hypoxia for 20 min. For hypoxia-reperfusion studies, brain slices were placed in normoxic aCSF solution for 45 min after the 20 min hypoxic stimulation and prior to initiating the biotinylation procedure. Slices were then cooled and treated with NHS-SS-Biotin (1 mg/ml, Thermo Scientific) for 1 h at 4 C. The biotin reaction was quenched with glycine buffer containing 192 mM Glycine and 25 mM Tris (pH 8.3). Slices were then homogenized in lysis buffer (pH 8.0) containing 50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM NaF; and the following protease inhibitors: 1 mM PMSF, 10 mg/mL aprotinin, 10 mg/mL pepstatin A, 10 mg/mL leupeptin, 2 mM Na 3 VO 4 , 20 mM sodium pyrophosphate, 3 mM benzamidine hydrochloride, and 4 mM glycerol 2-phosphate with 1% NP-40 detergent.
A Bradford Assay determined protein concentration in the lysates, and 500 mg of protein lysate diluted in lysis buffer was loaded into Streptavidin agarose beads (Thermo Scientific) and rotated overnight at 4 C. The proteins were eluted by adding 50 ml of 2X Laemmli sample buffer (Bio-Rad) and boiling the samples at 95 C for 5 min. Whole cell lysate samples of 50 mg were eluted in 20 ml of the same Laemmli buffer and boiled for 5 min. Samples were loaded into 10% SDS-PAGE gels and transferred from gels to Immobilon-P SQ transfer membranes (Millipore, 3 h at 4 C). Membranes were then treated with primary antibodies overnight at 4 C as follows: monoclonal mouse antiGluA1 (1:1000, Millipore), polyclonal rabbit anti-GluA1-pSer831
(1:1000, Millipore), polyclonal rabbit anti-GluA1-pSer845
(1:1000, Millipore), polyclonal rabbit anti-GluA2 (1:1000, Millipore), and monoclonal mouse anti-GAPDH (1:2000, Millipore).
Immunoblots were normalized to either whole-cell lysate levels of the protein of interest (for biotinylation) or GAPDH (for pSer831-GluA1 and pSer845-GluA1) as indicated in the Figure legends . Analysis was performed using Quantity One Basic (BioRad) and ImageJ (NIH, public domain). Statistical significance was assessed using a one-way ANOVA test and a TukeyeKramer multiple comparison test using GraphPad InStat version 3.0 (GraphPad).
Propidium iodide staining
Propidium iodide (PI) is an effective fluorescent marker for cell death due to the fact that it only enters and labels cells with disrupted plasma membranes (Pugliese et al., 2009 ). The methods used were adapted from Pugliese et al. (2009) . Hippocampal slices were pre-incubated in appropriate drug treatments for 1 h, followed by 20 min hypoxia and 3 h normoxic washout. In other studies, 500 nM CPA was applied for 30 min (with or without 45 min pre-incubation with 500 nM DPCPX) followed by a 3 h washout of the drug(s). In the final 1 h, 5 mg/ml PI (Sigma) was added to the aCSF. Following the incubation period, slices were rinsed thoroughly and fixed in 4% paraformaldehyde at 4 C overnight. The following day, slices were washed in 1X PBS and then mounted on glass microscope slides and treated with Prolong Gold Antifade Reagent (Invitrogen). After adding PI, all subsequent procedures were performed in the dark to prevent photobleaching. Imaging was performed using a Zeiss LSM700 laser scanning confocal microscope (Carl Zeiss, Germany) using green light (543 nm) to induce PI fluorescence. The whole hippocampus was imaged in pieces using a 10Â objective lens, and images of CA1 pyramidal neurons were obtained using the Zeiss Plan-Apochromat 63Â/1.4 oil objective lens (Carl Zeiss). CA1 images were acquired as Z-stack images of 200 mm depth into the hippocampal slice with each Z-stack image taken at 2 mm. Two Z-stack images were taken along CA1 for each slice and were averaged using densitometry analysis.
Data was collected using Zeiss Zen 2009 version 5.5 software (Carl Zeiss) and was analyzed using ImageJ. Z-stack images closest to the outer top and bottom of the hippocampal slices were not analyzed, as the neuronal damage in those areas was enhanced by the slicing procedure. An inner section of 20 mm (~100 mm deep) was analyzed using densitometry analysis. Full hippocampal images were assembled as montages of the entire hippocampal slice using Adobe Photoshop CS6 (Adobe Systems, Mountain View, CA).
Results
Inhibition of PP1, PP2A and PP2B prevented CPA-induced GluA1 internalization, whereas only PP2A inhibition prevented GluA2 internalization
We first sought to test the effect of A1R activation in hippocampal slices that were pre-incubated in PP1, PP2A, and PP2B inhibitors for 1 h followed by a 30 min treatment with the A1R agonist CPA (500 nM). We found in previous studies (Brust et al., 2007 (Brust et al., , 2006 Chen et al., 2014) , that the high concentration of CPA (500 nM vs. 50 nM) was ideal to produce a stronger activation of A1R-activated proteins including p38 MAPK, JNK, and PP2A, and to induce higher levels of AMPAR internalization and subsequent APSD. We previously showed that the PP2A inhibitors okadaic acid (20 nM) and fostriecin (20 nM) prevented A1R-induced GluA1 and GluA2 internalization (Chen et al., 2014) . In the present study, we applied general protein phosphatase inhibitor okadaic acid, PP2A-selective fostriecin, PP1-selective tautomycetin, and PP2B-selective FK506 at similar concentrations used by us and others in previous publications (Chen et al., 2014; H edou et al., 2008; Uchino et al., 2002) . Resultant Western blots show that hippocampal slices treated with tautomycetin, okadaic acid, fostriecin, and FK506 prevented the CPA-induced GluA1 internalization ( Fig. 1A and B) . All biotinylated blots were normalized to whole cell levels of the proteins of interest. Compared to CPA alone, which induced approximately 40% reduction in surface GluA1, phosphatase inhibitor treatments did not significantly alter GluA1 surface expression compared to control (100%). In contrast, CPA-induced GluA2 internalization was prevented by okadaic acid and fostriecin, but not by tautomycetin or FK506 (Fig. 1A and C) . Since the concentration of okadaic acid used may be selective for both PP2A and PP1, the effect of okadaic acid was compared to the effect of either fostriecin or tautomycetin. The results suggest that okadaic acid mimicked the effects of fostriecin in preventing GluA2 internalization, suggesting that PP2A activation alone was involved in CPA-induced GluA2 trafficking. The levels of GluA1 and GluA2 in whole lysates, when normalized to GAPDH, did not differ significantly in the different treatments for control, DMSO, okadaic acid, fostriecin, tautomycetin, and FK506 (data not shown). These data indicate that PP2A is involved in A1R-induced GluA1 and GluA2 internalization, whereas PP1 and PP2B are involved in GluA1 internalization but not GluA2 internalization after A1R activation.
PP1, PP2A and PP2B differentially reduce GluA1 phosphorylation at Ser831 and Ser845
Two C-terminal serine residues of GluA1, Ser831 and Ser845, are essential regulatory phosphorylation sites for GluA1 trafficking and function (Oh and Derkach, 2005; Roche et al., 1996) . We previously showed that Ser845 phosphorylation was decreased after treatment with a relatively large dose of the selective A1R agonist CPA (500 nM) but not with a GABA B receptor agonist baclofen (Chen et al., 2014) . To examine the role of PP1, PP2A and PP2B in A1R-mediated GluA1 dephosphorylation at both the Ser831 and Ser845 GluA1 residues, we tested the hypothesis that the phosphorylation state of Ser831 and Ser845 is modified by protein phosphatase inhibitor pre-incubation (above) before a 30 min CPA treatment. Western blots probed for phosphorylated GluA1 at either Ser831 or Ser845 (pSer831 and pSer845) showed that wholecell levels of pSer831 and pSer845 were significantly reduced after CPA treatment by 25% and 45%, respectively (Fig. 2) . In contrast, these protein phosphatase inhibitors did not significantly alter the total GluA1 levels ( Fig. 2A and C, middle blots) , suggesting that the reduction in surface GluA1 was not attributable to GluA1 protein degradation but likely to increased clathrin-mediated endocytosis as previously suggested (Chen et al., 2014) .
3.3. PP1, PP2A and PP2B mediate CPA-induced synaptic depression and APSD in hippocampal CA1
To examine the hypothesis that protein phosphatase inhibition prevents both CPA-induced synaptic depression and APSDs observed after CPA withdrawal, as described previously (Chen et al., 2014) , we performed fEPSP recordings in rat hippocampal slices. CA1 region fEPSP recordings were evoked from hippocampal slices pre-treated with protein phosphatase inhibitors (see above) for a minimum of 1 h prior to recording. In the absence of protein phosphatase inhibitors, the control (DMSO) slices showed a significant synaptic depression with CPA treatment (~80e90% synaptic depression, Fig. 3AeC ), which was blunted by pre-incubation of slices with the protein phosphatase inhibitors (Fig. 3C) . Similarly, in slices pre-incubated in vehicle control, approximately 50e60% of APSD was induced after a 1 h washout of CPA (Fig. 3A, B, and D) . Compared to control (DMSO), okadaic acid, fostriecin, FK506, and tautomycetin reduced the APSD levels to approximately 20e30% (Fig. 3D) . Although there was less synaptic depression and APSD in slices treated with phosphatase inhibitors, a residual APSD was still observed in protein phosphatase inhibitor-treated slices, indicating that protein phosphatases, although important, are not the only proteins involved in APSD generation.
3.4. Both GluA1 and GluA2 surface levels are reduced during hypoxia and contribute to neuronal damage Next, to test the hypothesis that the A1R-mediated GluA1 and GluA2 internalization and accompanying APSDs contribute to neuronal damage during hypoxia, we first confirmed that hypoxia caused similar changes as the A1R agonist CPA in altering the trafficking of AMPAR subunits. As shown in Fig. 4A , hypoxia reduced both GluA2 and GluA1 surface expression. We previously showed (Chen et al., 2014) that this was likely due to clathrinmediated internalization and required A1R activation. Surprisingly, we found that after a 45 min normoxic washout period, the levels of GluA1 increased while the levels of GluA2 remained depressed (Fig. 4B) . Moreover, the increased GluA1 surface expression was accompanied by increased pSer831 and pSer845 levels (Fig. 4C) . We then tested the hypothesis that the initial involvement of A1R-mediated protein phosphatase activation and downregulation of AMPAR surface expression during hypoxia represents the initial trigger for neuronal damage seen after normoxia-reperfusion.
To determine whether prolonged A1R signaling is sufficient to cause neuronal damage in hippocampal brain slices, we incubated slices in 500 nM CPA for 30 min, with or without a 45 min preincubation with the A1R antagonist DPCPX (500 nM). Subsequent washout of CPA for 3 h revealed significantly increased neuronal damage in all of hippocampal pyramidal neurons, which was blunted in the presence of DPCPX (Fig. 5A) . Similarly, a 20 min hypoxia followed by a 3 h normoxic washout revealed a significant A1R-dependent neuronal damage (Fig. 5B) . Finally, we then tested whether protein phosphatase activation (shown above to mediate GluA2 and GluA1 internalization and APSDs) is involved in the A1R-dependent hypoxia-induced neuronal death. As shown in Fig. 6 , the observed hypoxia-mediated neuronal death was largely prevented by treatment with inhibitors of PP2A (fostriecin, okadaic acid), PP1 (tautomycetin), and PP2B (FK506). Together, these results suggest that prevention of the initial A1R-mediated GluA2 and GluA1 internalization, in part by preventing protein phosphatase activation, may provide significant neuroprotection by preventing the formation of more GluA2-deficient (i.e., calcium-permeable) AMPARs during hypoxia-reperfusion injury.
Discussion
The signaling mechanisms that regulate A1R-mediated AMPAR trafficking and the functional importance of this regulation in neurotoxicity are not well elucidated. In this study, we investigated the role of protein phosphatases 1, 2A and 2B in adenosine A1R-mediated synaptic depression and hypoxia/reperfusion injury in rat hippocampal slices, and their role in regulating AMPAR surface expression. We showed that these three serine/threonine protein phosphatases mediated A1R-induced GluA2 and GluA1 endocytosis. PP1, PP2A and PP2B inhibition reduced CPA-induced GluA1 internalization, but only PP2A inhibition prevented CPA-induced GluA2 endocytosis. Accordingly, the levels of GluA1 pSer831 and pSer845 were reduced following CPA treatment. Specifically, the reduction in pSer831 was sensitive to PP1 and PP2B inhibitors, whereas the reduction in pSer845 was only preventable by treatment of hippocampal slices with PP2A inhibitors. Along with reducing AMPAR surface expression, prolonged A1R activation induced APSDs as previously shown (Chen et al., 2014) and confirmed in the present study, and these changes were blunted by pre-treatments of hippocampal slices in PP1, PP2A or PP2B inhibitors. Protein phosphatase activation following A1R stimulation was shown to promote neuronal damage in both CPA-and hypoxiatreated hippocampal brain slices. Slices subjected to 20 min hypoxia followed by a 45 min normoxic reperfusion/washout showed increased surface GluA1, without affecting the decreased levels of surface GluA2. Together, our results suggest that A1R-mediated activation of protein phosphatases during hypoxic insult contributes to the subsequent formation of GluA2-deficient AMPARs and increased GluA1-containing AMPARs during normoxic reperfusion injury, which triggers neuronal death.
PP1, PP2A and PP2B have been shown to contribute to the modulation of excitatory neurotransmission and learning and memory processes throughout the brain through a multitude of intracellular mechanisms (Belmeguenai and Hansel, 2005; Lin et al., 2000; Mulkey et al., 1993) . For example, PP1 activity has been shown to mediate the induction of long term potentiation and long term depression (Allen et al., 2000; Li and Pan, 2013) , and has been shown to directly regulate AMPA receptors in the brain (Yan et al., 1999) . In addition to previously described A1R-induced increase in active PP2A in hippocampal membrane fractions (Brust et al., 2006) , PP2A has also been shown to mediate multiple functions in the brain which includes direct modulation of AMPARs Fig. 1 . PP1, PP2A, and PP2B inhibitor treatment reduced CPA-induced GluA1 internalization, and PP2A inhibition reduced CPA-induced GluA2 internalization. (A) Representative biotinylated Western blots of hippocampal slices exposed to 30 min CPA treatment (500 nM) with pre-incubation in okadaic acid (20 nM), fostriecin (20 nM), tautomycetin (20 nM), and FK506 (50 nM). (B) Summary bar graph showing that GluA1 surface expression was reduced by approximately 40% after CPA treatment with no other drugs added, and treatment with protein phosphatase inhibitors for 1 h prior to CPA treatment significantly reduced CPA-induced GluA1 internalization. Whole lysates probed for GluA1 showed constant levels across all treatments. (C) Summary chart for GluA2 expression show that CPA treatment reduced GluA2 surface expression, and treatment with okadaic acid and fostriecin, PP2A inhibitors, prevented CPA-induced GluA2 internalization, with fostriecin significantly preventing GluA2 internalization compared to CPA alone. Treatment with tautomycetin and FK506 did not prevent GluA2 internalization. Whole lysate levels of GluA2 did not significantly change. Whole lysate blots were normalized to intracellular GAPDH. Graphed values are shown as mean ± SEM, n ¼ 4e6 independent experiments, *P < 0.05, **P < 0.01 and ***P < 0.005. (Launey et al., 2004) . It has also been shown that the levels of the regulatory B subunit of PP2A is decreased after focal ischemia, which indicates increased PP2A activity (Koh, 2011) . Finally, PP2B, a Ca 2þ -dependent protein phosphatase, has been implicated in the induction of neurotoxicity in ischemia (Ankarcrona et al., 1996; Asai et al., 1999) , whereas inhibition of PP2B with FK506 has been reported to be an effective neuroprotective treatment (Bochelen et al., 1999; Butcher et al., 1997; Sharkey and Butcher, 1994; Uchino et al., 2002) . In this study, we add to the wide list of functions performed by these three ubiquitous protein phosphatases. Specifically, our results suggest that protein phosphatase activation contributes to the generation of the A1R-induced persistent synaptic depression (or APSD) observed after prolonged washout of the A1R agonist. Whether the level of APSDs directly correlates with the level of subsequent neuronal death remains unclear. However, we found that several protein phosphatase inhibitors, which were successful in depressing the APSD levels, were also effective in inhibiting hippocampal neuronal damage. Our results also suggest that PP2A activation after A1R stimulation selectively downregulated GluA2 surface expression and mediated GluA1 pSer845 dephosphorylation. In contrast, PP1 and PP2B inhibitors, though effective in attenuating the reduction in GluA1 surface expression, were only effective in preventing GluA1 pSer831 dephosphorylation. Therefore, different serine/threonine protein phosphatases appear to be involved in the differential regulation of AMPAR trafficking and AMPAR phosphorylation levels after A1R stimulation. To rule out nonspecific effects of the pharmacological inhibitors used in our study, future studies involving knockdown of genes encoding for PP2A, PP1 or PP2B are required to further establish or confirm the requirement of protein phosphatase activation in the A1R-mediated AMPAR surface trafficking and neuronal cell death in ischemic conditions. It is also important to identify the upstream signaling cascades that mediate the A1R-mediated protein phosphatase activation, and whether activation of PP1, PP2A or PP2B is accomplished in parallel or in sequential manner by upstream mediators.
We recently showed that p38 MAPK and JNK mediated A1R-induced GluA2, but not GluA1, endocytosis, whereas PP2A was involved in both GluA1 and GluA2 endocytosis (Chen et al., 2014) . The results of the present study show a novel mechanism by which adenosine A1R activation increases protein phosphatase activity, which leads to increased GluA2 and GluA1 internalization during hypoxic injury. However, we found that a subsequent normoxiareperfusion period led to increased phosphorylation of GluA1 at both Ser831 and Ser845, which is consistent with our observation of enhanced GluA1 surface expression. This increase in GluA1 surface expression, coupled with the persistent downregulation of GluA2 surface expression, may play a role in the increased calcium permeability of surface expressed AMPARs which leads to the observed increase in hippocampal neuronal death following hypoxia-reperfusion injury. However, the signaling mechanisms underlying this increased GluA1 surface expression during reperfusion injury remains to be defined. The Ser831 and Ser845 of GluA1 subunits are known targets of PKC/CaMKII and PKA, Fig. 2 . Dephosphorylation of GluA1 at Ser831 and Ser845 is mediated by A1R-induced protein phosphatases 1, 2A and 2B activity. (A) Representative whole lysate blots of hippocampal lysates treated with okadaic acid (20 nM), fostriecin (20 nM), tautomycetin (20 nM), or FK506 (50 nM) for 1 h prior to additional 30 min CPA treatment and probed sequentially for pSer831-GluA1, GluA1 and GAPDH. (B) Phosphorylated Ser831 was reduced after CPA treatment, and tautomycetin and FK506 nullified this effect. GluA1 expression was not significantly different between treatments. (C) Representative blots, sequentially probed for pSer845-GluA1, GluA1 and GAPDH, show that CPA treatment also significantly reduced levels of pSer845, which was prevented by okadaic acid and fostriecin treatment. Tautomycetin and FK506 did not prevent this CPA-induced reduction in pSer845. (D) Summary bar graphs show that pSer845 was significantly reduced by CPA treatment in absence or presence of tautomycetin or FK506, and this reduction was prevented by either okadaic acid or fostriecin. N ¼ 3 independent blots/experiments. Average values are mean ± SEM, Significance values: *P < 0.05, **P < 0.01 and ***P < 0.005. respectively (Esteban et al., 2003; Gu et al., 1996; He et al., 2011) . Previous reports also suggested that A1R activation leads to increased translocation of specific PKC isoforms to cardiac myocyte lipid raft microdomains (Yang et al., 2009 ) and that A1R activation causes PKC-mediated increase in nucleoside transporter surface expression and function in porcine epithelial cell lines (Hughes et al., 2015) . Moreover, in hippocampal brain slices, A2AR activation has been reported to increase the function of adenosine nucleoside transporters through a PKC-dependent process (PintoDuarte et al., 2005) . Therefore, based on these previous studies, it is possible that the enhanced pSer831 GluA1 levels may be related to activation of either A1R or A2AR or simultaneous activation of both receptors, which leads to indirect activation of PKC and subsequently increased pSer831 GluA1 subunits. On the other hand, A2AR activation has been previously shown to cause increased hippocampal GluA1, but not GluA2, surface expression (Chen et al., 2014) , as well as PKA-dependent increase in pSer845 GluA1 levels and GluA1-mediated AMPAR currents (Dias et al., 2012) . In addition, in our in vivo focal cortical stroke model using the pial vessel disruption procedure (Cayabyab et al., 2013; Chen et al., 2014) , we observed increased A2AR surface expression, but decreased A1R surface expression, two days after the pial vessel disruption stroke injury. Together, our results showing increased levels of pSer831 and pSer845 GluA1 subunits after normoxic/reperfusion injury may be attributable to indirect activation of both PKC and PKA by different levels of A1R and A2AR stimulation. Our results also suggest that the prior A1R stimulation during hypoxic insult (or during direct A1R activation with CPA) and the concomitant activation of serine/threonine protein phosphatases constitute the initial trigger for the A1R-mediated decrease in GluA2 and GluA1 surface expression and the generation of APSDs, which contribute to neuronal damage. However, it will be important in future studies to further identify the pro-neurotoxic signaling pathways activated by A1R stimulation that may impact A1R and A2AR trafficking and signaling to AMPAR subunits.
The precise contribution of serine/threonine protein phosphatases in A1R-mediated neurodegeneration in hypoxic/ischemic injury has not been reported. Previous studies have described the involvement of the serine/threonine protein phosphatases in various ischemia-induced cellular mechanisms in the brain (Cid et al., 2007; Don Yi and Simpkins, 2008; Rund en et al., 1998) . For example, PP1, PP2A, and PP2B were shown to play a role in estrogen-mediated neuroprotection in ischemia, where estrogen was observed to promote maintenance of the protein expression On the other hand, the fEPSP slopes for slices treated with protein phosphatase inhibitors was significantly higher at the end of the washout period. n ¼ 7e10 slices were recorded for each treatment group from different rats. Graphed values are shown as mean ± SEM. Significance values: * ¼ p < 0.05, ** ¼ p < 0.01, *** ¼ p < 0.001. levels and activities of these three protein phosphatases in the transient middle cerebral artery occlusion stroke model (Don Yi and Simpkins, 2008) . However, it remains unclear whether this neuroprotective effect of estrogen on ischemic stroke is linked to maintained protein expression, phosphorylation status, or function of glutamate receptors, including AMPARs and NMDARs. Another previous report (Zhu et al., 2012) suggested that simvastatin can also promote neuroprotection in ischemic stroke by reducing Ca 2þ influx through NMDARs and increasing expression levels of PP2A. In in vitro ischemic models, oxygen glucose deprivation and subsequent normoxic reperfusion have been shown to cause increased expression of Ca 2þ -permeable AMPARs (Dias et al., 2013) and increased levels of neuronal damage (Pugliese et al., 2009) , which can be prevented by administration of an A2AR antagonist SCH 58261. Dias and colleagues also reported an A2AR-dependent increase in GluA1 surface expression and GluA1-mediated AMPA currents, which were accompanied by increased pSer845 levels (Dias et al., 2012) . In the present study, the 20 min hypoxia followed by a 45 min normoxic reperfusion led to persistent downregulation of GluA2 surface expression but produced an increase in GluA1 surface expression as well as increased pSer831 and pSer845 levels, raising the possibility that decreased protein phosphatase activity or localization to synaptic sites and/or increased A2AR activation may also lead to the formation of Ca 2þ -permeable AMPARs and subsequently enhanced hypoxia-reperfusion injury. Additionally, hypoxia-inducible factors (HIFs), which have increased activity in hypoxia, have been suggested to interact with the adenosine signaling pathway in immune cells (Sitkovsky et al., 2004) . This interaction may also occur through A1R/A2AR-dependent activation of MAPK's, which may activate HIF-1a in cultured neuronal cells (Thauerer et al., 2012 ). Since we previously showed that A1R activates p38 MAPK and JNK, future studies are required to determine whether MAPK activation using A1R agonists or hypoxia in hippocampal slices also result in HIF-1a activation. Whether this leads to neuroprotection or neurodegeneration remains to be elucidated. Together, these in vivo and in vitro models of cerebral ischemia suggest that decreased levels of serine/threonine protein phosphatases may contribute to protracted hyperphosphorylation of target substrates, including AMPARs. However, future studies are required to confirm whether a prior activation of A1Rs during hypoxia then triggers the subsequent A2AR-dependent stimulation Fig. 5 . Adenosine A1R activation with CPA or endogenous adenosine receptor stimulation during hypoxia produced significant neuronal death in hippocampal slices, which was prevented by pre-treatments with A1R antagonist DPCPX. (A) Representative confocal microscopy images showing propidium iodide (PI)-labeled hippocampal slices subjected to a 30 min CPA treatment (500 nM). Significant neuronal death was seen with CPA treatment alone, but DPCPX (500 nM) pre-treatment was sufficient to significantly prevent this neuronal death. Summary bar graph (right) shows relative densitometry values for PI fluorescence compared with neuronal death caused by CPA (100%). (B) PI-stained hippocampal slices that were treated with 20 min hypoxia also showed significant neuronal death, which was also prevented by pre-treatment with 500 nM DPCPX. n ¼ 5 independent experiments, using 5 rats per experiment. Scale bars: 1 mm (whole hippocampus, left column) and 10 mm (CA1, right column, boxed region in left column) apply to A and B. Values are shown as mean ± SEM. Significance values: *** ¼ p < 0.005.
of Ca 2þ -permeable AMPARs during the hypoxia-reperfusion period.
If so, these data would indicate a novel mechanism that not only GluA1-containing AMPARs and A2ARs are key mediators of reperfusion injury to neurons by inducing increased Ca 2þ permeability of AMPARs, but also that persistent A1R-mediated downregulation of GluA2-containing AMPARs (i.e., calcium-permeable) are also critical for promoting neurotoxicity.
Conclusion
In summary, our studies have shown an A1R-mediated differential regulation of AMPAR subunit expression during and after hypoxia that contributes to increased vulnerability of hippocampal neurons to ischemic damage. We have shown that protein phosphatase inhibitors reduced A1R-mediated AMPAR internalization and APSDs. However, our results with hypoxia and subsequent reperfusion revealed a persistent downregulation of GluA2 surface expression, whereas GluA1 was upregulated only during reperfusion. Although these changes in AMPAR subunits would be predicted to lead to increased neuronal death, as we have shown in this study, it is surprising that these changes appeared to depend on a prior A1R activation (during hypoxia). Future studies are needed to determine whether a possible cross-talk between A1R and A2AR exists to modulate AMPAR trafficking and neuronal death in ischemia. In addition, since we recently found that p38 MAPK and JNK can also mediate A1R-induced GluA2 internalization (Chen et al., 2014) and protein phosphatase inhibition alone produced incomplete prevention of APSDs and neuronal damage (present study), future studies will be needed to determine whether inhibition of these MAPKs in combination with protein phosphatase inhibition can be a viable treatment option for ischemic brain damage. Therefore, this previously unrecognized role of A1R-mediated excitotoxic potential caused by altering AMPAR subunit compositions that promote hippocampal neuronal death in hypoxia-reperfusion injury, represents a novel therapeutic target in cerebral ischemic damage.
